April 9, 2024 7:06am

News: BrainStorm Cell Therapeutics (BCLI closed +$0.079, pre-market +$0.16) received written agreement from the U.S.FDA), under a Special Protocol Assessment (SPA), on the design for a P3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS). <continued below>

Pre-open Indicators: 1 Sell into Strength, 2 Positive and 1 Negative Indicators

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone and new website!

A string of reports showing inflation and the economy have remained hotter than expected has forced the “Street” to delay forecasts for when relief on rates could arrive

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility!

My version of the morning’s numbers is written to be informative; it’s including what happened or will beyond the headline and shapes today’s potential sector response as seen by RMi.

 

Tuesday: The pre-open Dow futures are DOWN -0.13% or (-52 points), the S&P futures are DOWN -0.10% or (-4 points) as the Nasdaq futures are DOWN -0.11% or (-19 points)

Stock futures were down and skipping on Tuesday, April 9, 2024,

European markets were lower,

Asia-Pacific markets were mixed.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Monday: The Dow closed DOWN -11.24 points or -0.03%, the S&P closed DOWN -1.95 points or -0.04% while the Nasdaq closed UP +5.43 points or +0.03%

Economic Data Docket: Consumer Price Index and minutes from the Fed's March policy mee on Wednesday

  • CPI is expected to show a slight cooldown in monthly price growth and a nominal decrease in the annual core number, which excludes volatile food and energy items.

BrainStorm Cell Therapeutics (BCLI) Continued from title: The SPA agreement with the FDA validates the clinical trial protocol and statistical analysis of the planned Phase 3b trial of NurOwn, demonstrating their adequacy for addressing objectives that support a future BLA (Biologics License Application) in ALS.

 

Monday’s night RegMed Investors (RMi) Closing Bell: what’s moving the sector? A slow walk to a closing with divided views of share pricing, Fed speakers, growing clatter about the coming US presidential election, and a spike in oil prices and treasury yields.” … https://www.regmedinvestors.com/articles/13408

 

Q2/24:  April - 5 negative and 1 positive closes

Q1/24:

  • March – 8 positive and 12 negative closes
  • February – 1 market holiday, 11 positive and 9 negative closes
  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength Indications:

Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed up +$2.48 after Friday’s +$2.08 with a positive =$0.05 or +0.03% pre-open indication.

 

Positive Indications:

Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

BrainStorm Cell Therapeutics (BCLI) closed up +$0.079 with a positive, pre-market +$0.16 or +21.37% after receiving written agreement from the U.S.FDA), under a Special Protocol Assessment (SPA), on the design for a P3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS).

Verve Therapeutics (VERV) closed down -$0.12 after Friday’s -$0.16 with a positive +$0.04 or +0.60% pre-open indication.

 

Negative Indications:

Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Solid Biosciences (SLDB) closed down -$0.26 after Friday’s -$0.22 with a negative -$0.15 or -1.26% pre-open indication.

 

 

The BOTTOM LINE: Back to the beginning post earnings, as I stated in the title; WHERE, WHAT and WHEN are the catalysts to move share pricing

Need more … and then more!

My advice: keep opening that portfolio envelope and think of a game of monopoly and follow RMi’s moves to gain profitable moves or recoup losses.

  • A bit preachy, “The take-away, don’t dwell on what’s happened and follow RMi’s lesson of investing in those who guide and then meet short-term expectation.”

Trader angst centers on a bunch of unknowns: The focus on interest rates and when the Fed will lower them, geopolitical tensions, the upcoming US presidential election, Q1 earnings reports.

Monday night’s insight into Tuesday:

  • Indexes: Dow off 0.03%, S&P down 0.04%, Nasdaq up 0.03%
  • The yield on the 10-year Treasury stood at 4.42% following a bond sell-off last week.
  • For the year, The Nasdaq is up 1,242.60 points, or 8.3% and the Russell 2000 is up 46.64 points, or 2.3%.

Key word of the state of uncertainty in “our” universe of cell and gene therapy … “which makes It difficult to predict where sector is headed in the short run.”

  • I STILL believe the political aspect of the country’s polarization, and disparities of the debt ceilings and rate hike arguments are contributing to the roller coaster ride for share pricing actions
  • Investors should still be cautious in the current downslide sector, yet I still see some oversold equities especially with today's jobs report on the horizon.

Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.